Intent To Grant an Exclusive License of U.S. Government-Owned Patents

Federal Register, Volume 80 Issue 225 (Monday, November 23, 2015)

Federal Register Volume 80, Number 225 (Monday, November 23, 2015)

Notices

Page 72954

From the Federal Register Online via the Government Publishing Office www.gpo.gov

FR Doc No: 2015-29778

=======================================================================

-----------------------------------------------------------------------

DEPARTMENT OF THE ARMY

Intent To Grant an Exclusive License of U.S. Government-Owned Patents

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license to US Provisional Patent Application 62/131,444, filed March 11, 2015, entitled, ``A method for developing malaria sporozoites in vitro'' to MalarVx, Inc., a for profit corporation, having a principal place of business at 307 Westlake Avenue North, Suite 200, Seattle, WA 98109.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For licensing issues, Mr. Barry Datlof, Office of Research & Technology Assessment, (301) 619-0033. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES).

Brenda S. Bowen,

Army Federal Register Liaison Officer.

FR Doc. 2015-29778 Filed 11-20-15; 8:45 am

BILLING CODE 3710-08-P

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT